



Addendum Definiering Risicogroepen



Bron CDC COVID –Net (USA data). <https://gis.cdc.gov/grasp/COVIDNet>



Bron CDC COVID –Net

Omschrijving Risicogroepen door CDC

“People of any age with **certain underlying medical conditions** are at increased risk for severe illness from COVID-19:

People of any age with the following conditions **are at increased risk** of severe illness from COVID-19:

- Cancer
- Chronic kidney disease
- COPD (chronic obstructive pulmonary disease)
- Immunocompromised state (weakened immune system) from solid organ transplant
- Obesity (body mass index [BMI] of 30 or higher)
- Serious heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies
- Sickle cell disease
- Type 2 diabetes mellitus

COVID-19 is a new disease. Currently there are limited data and information about the impact of underlying medical conditions and whether they increase the risk for severe illness from COVID-19. Based on what we know at this time, people with the following conditions **might be at an increased risk** for severe illness from COVID-19:

- Asthma (moderate-to-severe)
- Cerebrovascular disease (affects blood vessels and blood supply to the brain)
- Cystic fibrosis
- Hypertension or high blood pressure
- Immunocompromised state (weakened immune system) from blood or bone marrow transplant, immune deficiencies, HIV, use of corticosteroids, or use of other immune weakening medicines
- Neurologic conditions, such as dementia
- Liver disease
- Pregnancy
- Pulmonary fibrosis (having damaged or scarred lung tissues)
- Smoking
- Thalassemia (a type of blood disorder)
- Type 1 diabetes mellitus”

Level of Evidence	Condition	Evidence of Impact on COVID-19 Severity	Notes
Strongest and Most Consistent Evidence	Serious heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies	Cohort Study [1, 2] Meta Analyses [3, 4] Case Series [5]	On previous version of list as "Serious Heart Conditions"
	Cancer	Systematic Review [6] Cohort Study [7, 8] Case Series [9]	New to updated list as of July 17, 2020
	Chronic kidney disease	Case Series [10, 11, 12] Cohort Studies [13, 14, 15]	On previous version of list as "Chronic Kidney Disease Requiring Dialysis"
	COPD	Meta Analyses [4, 16] Case Series [17] Cohort Study [14]	On previous version of list
	Obesity (BMI $\geq$ 30)	Cohort Studies [18, 19, 20, 21, 22] Cross-sectional [23]	On previous version of list as "Severe Obesity (BMI $\geq$ 40)"
	Sickle cell disease	Case Series [24, 25, 26, 27, 28]	On previous version of list
	Solid organ transplantation	Case Series [12, 29, 30, 31, 32, 33, 34]	New to updated list as of June 25, 2020
	Type 2 diabetes mellitus	Case Series [11] Longitudinal Study [35] Cohort Study [36, 37] Meta Analysis [38]	On previous version of list
Mixed Evidence	Asthma	Cohort Study [14, 39, 40, 41] Case Series [17]	On previous version of list
	Cerebrovascular disease	Meta Analysis [42, 43, 44, 45] Synthesis of Evidence [46] Cohort Study [1, 2, 47, 48, 49]	New to updated list as of June 25, 2020
	Hypertension	Cohort Study [1, 2, 49, 50, 51] Systematic Review [52] Meta Analyses [3, 4, 53]	New to updated list as of June 25, 2020
	Pregnancy	Systematic Review [54] Case Control Study [55] Case Series [56, 57, 58, 59] Cohort Study [60, 61, 62]	
	Smoking	Meta Analyses [3, 63, 64, 65, 66]	On previous version of list
Limited Evidence	Bone marrow transplantation	Review [72]	On previous version of list
	HIV	Case Series [73, 74]	On previous version of list
	Immune deficiencies	Case Series [75] Systematic Review [76]	On previous version of list
	Inherited metabolic disorders	Cohort Study [47, 77]	New to updated list as of June 25, 2020: specific to pediatric populations at this time
	Liver disease	Meta-Analysis [78] Cohort Study [79, 80] Literature Review [81]	On previous version of list
	Neurologic conditions	Cross-Sectional Study [82] Cohort Study [41, 49, 77]	New to updated list as of June 25, 2020: specific to pediatric populations at this time
	Other chronic lung diseases	Meta-Analysis [4] Case Series [17] Cohort Study [14, 83]	On previous version of list
	Pediatrics	Systematic Review [84, 85] Cross-Sectional Study [82, 86] Cohort Study [77, 87, 88]	New to updated list as of July 17, 2020
	Thalassemia	Case Series [89] Cross-Sectional Study [90]	On previous version of list
	Type 1 diabetes mellitus	Case Series [11] Cohort Study [36, 37] Meta-Analysis [38]	On previous version of list

Omschrijving risicogroepen door UK

People at high risk (clinically extremely vulnerable)

People at high risk from coronavirus include people who:

- have had an organ transplant
- are having chemotherapy or antibody treatment for cancer, including immunotherapy
- are having an intense course of radiotherapy (radical radiotherapy) for lung cancer
- are having targeted cancer treatments that can affect the immune system (such as protein kinase inhibitors or PARP inhibitors)
- have blood or bone marrow cancer (such as leukaemia, lymphoma or myeloma)
- have had a bone marrow or stem cell transplant in the past 6 months, or are still taking immunosuppressant medicine
- have been told by a doctor they have a severe lung condition (such as cystic fibrosis, severe asthma or severe COPD)
- have a condition that means they have a very high risk of getting infections (such as SCID or sickle cell)
- are taking medicine that makes them much more likely to get infections (such as high doses of steroids or immunosuppressant medicine)
- have a serious heart condition and are pregnant

Information:

If you're at high risk from coronavirus, you should have received a letter from the NHS.

Speak to your GP or hospital care team if you have not been contacted and think you should have been.

What to do if you're at high risk

If you're at high risk from coronavirus, you were advised to take extra steps to protect yourself until 1 August 2020. This was called shielding.

In England, you're no longer advised to shield. But there are still things you can do to protect yourself and others. You can also still get some support.

See what to do if you're at high risk from coronavirus.

People at moderate risk (clinically vulnerable)

People at moderate risk from coronavirus include people who:

- are 70 or older
- have a lung condition that's not severe (such as asthma, COPD, emphysema or bronchitis)
- have heart disease (such as heart failure)
- have diabetes
- have chronic kidney disease

- have liver disease (such as hepatitis)
- have a condition affecting the brain or nerves (such as Parkinson's disease, motor neurone disease, multiple sclerosis or cerebral palsy)
- have a condition that means they have a high risk of getting infections
- are taking medicine that can affect the immune system (such as low doses of steroids)
- are very obese (a BMI of 40 or above)
- are pregnant – see advice about pregnancy and coronavirus

What to do if you're at moderate risk

If you're at moderate risk from coronavirus, you can go out to work (if you cannot work from home) and for things like getting food or exercising. But you should try to stay at home as much as possible.

It's very important you follow the general advice on [social distancing](#). This includes trying to stay at least 2 metres (3 steps) away from anyone you do not live with or anyone not in your support bubble.

What is a support bubble?

Europa/ECDC

3 Risk groups most affected

3.1 Preconditions: frequency distribution by severity

Show 20 entries

Search:

Precondition	Mild	Mild (%)	Hospitalised	Hospitalised (%)	Severe	Severe (%)	Fatal	Fatal (%)
None	44113	79.9	19475	41.1	1607	23	1567	12.5
Cardiac disorder, excluding hypertension	2213	4	5676	12	1424	19.3	2014	16
Diabetes	1645	3	5447	11.5	1342	18.2	1778	14.1
Chronic lung disease, excluding asthma	1636	3	2937	6.2	644	8.7	1158	9.2
Current smoking	1079	2	215	0.5	47	0.6	32	0.3
Hypertension	1031	1.9	4223	8.9	626	8.5	2311	18.4
Asthma	855	1.5	1482	3.1	259	3.5	542	4.3
Neuromuscular disorder, chronic neurological	766	1.4	1759	3.7	293	3.4	904	7.2
Cancer, malignancy	750	1.4	1922	4.1	312	4.2	674	5.4
Kidney-related condition, renal disease	318	0.6	1949	4.1	372	5	1022	8.1
HIV / other immune deficiency	299	0.5	764	1.6	157	2.1	229	1.8
other endocrine disorder (excl. Diabetes)	118	0.2	122	0.3	17	0.2	21	0.2
Obesity	100	0.2	324	0.7	48	0.6	18	0.1
Hematological disorders	78	0.1	319	0.7	40	0.5	80	0.6
Rheumatic diseases including arthritis	28	0.1	30	0.1	3	0	3	0
Asplenia	2	0	3	0	1	0	1	0
Tuberculosis	2	0	11	0	0	0	3	0
Total	55210	100	47407	100	7392	100	12578	100

BRON: ECDC

Referenties Risicogroepen

<https://covid19-surveillance-report.ecdc.europa.eu/>

<https://gis.cdc.gov/grasp/COVIDNet>

<https://www.nhs.uk/conditions/coronavirus-covid-19/people-at-higher-risk/whos-at-higher-risk-from-coronavirus/>

<https://www.hiqa.ie/reports-and-publications/health-technology-assessment/rapid-review-protective-measures-vulnerable>

Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020 *Weekly* / March 27, 2020 / 69(12);343-346

Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China [Chinese]. Chinese Center for Disease Control and Prevention *Weekly* 2020;41:145–51.

Wu C et al, Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med.* 2020 Mar 13.

Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020. *Weekly* / April 3, 2020 / 69(13);382–386
CDC COVID-19 Response Team

Liang W, et al, Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol.* 2020;21:335-337

Wei-jie Guan et al , Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis, *Eur. Resp J.* 2020, Mar26:2000547

Anastasia Vishnevetsky and Michael Levy , Rethinking high-risk groups in COVID-19, *Mult Scler Relat Disord.* 2020 Apr 22 : 102139.

Amir Emami, Fatemeh Javanmardi, Neda Pirbonyeh, and Ali Akbari. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis, *Arch Acad Emerg Med.* 2020; 8(1): e35.

Hanping Wang et al, Risk of COVID-19 for patients with cancer. *The Lancet Oncology*, Mar 03, 2020

Tao Chen, Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study, *BMJ* 2020; 368

Jordan, R.E., Covid-19: risk factors for severe disease and death, *BMJ* 2020; 368

Sara Monti et al, Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies, <http://orcid.org/0000-0002-1800-6772>, *Annals of the Rheum Dis.*; Vol 79, Issue 5

Zhou F et al, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020 Mar 28;395(10229):1054-1062

Yuanyuan Han,^{a,1} Mao Jiang,^{a,1} Da Xia,^b Lichao He,^b Xin Lv,^c Xiaohua Liao,^c and Jie Meng^{a,*} COVID-19 in a patient with long-term use of glucocorticoids: A study of a familial cluster, *Clin Immunol*. 2020 May; 214: 108413.

Guillen E, et al. Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation? *Am J Transplant*. 2020 Mar 20

Zhu L et al, Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China. *Eur Urol*. 2020 Apr 18.

Minotti C et al, *J Infect*. 2020 Apr 23.

How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review.

Fishman JA et al, Novel Coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve. *Am J Transplant*. 2020 Mar 31.

Mehra et al COVID and heart failure. *JACC Heart failure* volume. 2020

Quinti et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. *J Allergy and Clinical Immunology*. 2020 Jul; 146(1): 211–213.e4.

Chen, R., et al., *Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 from a Nationwide Analysis in China*. CHEST.

Williamson, E., et al., *OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients*. medRxiv, 2020: p. 2020.05.06.20092999.

Zheng, Z., et al., *Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis*. *Journal of Infection*, 2020.

Yang, J., et al., *Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis*. *International Journal of Infectious Diseases*, 2020. 94: p. 91-95.

Guo, T., et al., *Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)*. *JAMA Cardiology*, 2020.

Fung M, Babik JM. COVID-19 in Immunocompromised Hosts: What We Know So Far [published online ahead of print, 2020 Jun 27]. *Clin Infect Dis*. 2020;ciaa863. doi:10.1093/cid/ciaa863

Robilotti, Elizabeth V et al. "Determinants of COVID-19 disease severity in patients with cancer." *Nature medicine*, 10.1038/s41591-020-0979-0. 24 Jun. 2020, doi:10.1038/s41591-020-0979-0

Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol*. 2020;21(3):335-337

Zhang H, Wang L, Chen Y, et al. Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China [published online ahead of print, 2020 Jun 23]. *Cancer*. 2020;10.1002/cncr.33042. doi:10.1002/cncr.33042.

Garg, S., et al., *Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 – COVID-NET, 14 States*, March 1-30, 2020. MMWR Morbidity Mortality Weekly Report, 2020. 69(15): p. 458-464.

Richardson, S., et al., *Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area*. JAMA, 2020. 323(20): p. 2052-2059.

Akalin, E., et al., *Covid-19 and Kidney Transplantation*. New England Journal of Medicine, 2020.

Myers, L.C., et al., *Characteristics of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California*. JAMA, 2020. 323(21): p. 2195-2198.

Gold, J.A.W., et al., *Characteristics and Clinical Outcomes of Adult Patients Hospitalized with COVID-19 – Georgia, March 2020*. MMWR Morbidity Mortality Weekly Report, , 2020. 69(18): p. 545-550.

Hirsch, J.S., et al., *Acute kidney injury in patients hospitalized with COVID-19*. Kidney international, 2020: p. S0085-2538(20)30532-9.

Lippi, G. and B.M. Henry, *Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19)*. Respiratory medicine, 2020. 167: p. 105941-105941.

Lighter, J., et al., *Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission*. Clinical Infectious Diseases, 2020.

Simonnet, A., et al., *High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation*. Obesity (Silver Spring), 2020.

Kalligeros, M., et al., *Association of Obesity with Disease Severity Among Patients with Coronavirus Disease 2019*. Obesity, 2020(n/a).

Palaodimos, L., et al., *Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York*. Metabolism, 2020. 108: p. 154262.

Petrilli, C.M., et al., *Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City*. medRxiv, 2020: p. 2020.04.08.20057794.

McCloskey, K.A., et al., *COVID-19 infection and sickle cell disease: a UK centre experience*. British Journal of Haematology.

Heilbronner, C., et al., *Patients with sickle cell disease and suspected COVID-19 in a paediatric intensive care unit*. British Journal of Haematology.

Nur, E., et al., *Vaso-occlusive crisis and acute chest syndrome in sickle cell disease due to 2019 novel coronavirus disease (COVID-19)*. American Journal of Hematology, 2020. 95(6): p. 725-726.

Hussain, F.A., et al., *COVID-19 infection in patients with sickle cell disease*. British Journal of Haematology, 2020. 189(5): p. 851-852.

Panepinto et al., *Cases of COVID-19 among Persons with Sickle Cell Disease in the United States, March 20-May 21, 2020*. Personal Pre-Publication Correspondence with Authors 2020.

Ketcham, S.W., et al., *Coronavirus Disease-2019 in Heart Transplant Recipients in Southeastern Michigan: A Case Series*. Journal of Cardiac Failure, 2020.

Latif, F., et al., *Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019*. JAMA Cardiology, 2020.

Fernández-Ruiz, M., et al., *COVID-19 in solid organ transplant recipients: A single-center case series from Spain*. American Journal of Transplantation.

Travi, G., et al., *Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience*. American Journal of Transplantation, 2020.

Tschopp, J., et al., *First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study*. American Journal of Transplantation.

Zhu, L., et al., *Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes*. Cell Metabolism, 2020. 31(6): p. 1068-1077.e3.

Bode, B., et al., *Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States*. Journal of Diabetes Science and Technology, 2020: p. 1932296820924469.

Chen, Y., et al., *Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication*. Diabetes Care, 2020.

Fadini, G.P., et al., *Prevalence and impact of diabetes among people infected with SARS-CoV-2*. J Endocrinological Investigations, 2020. 43(6): p. 867-869.

Mahdavinia, M., et al., *Asthma prolongs intubation in COVID-19*. The journal of allergy and clinical immunology. In practice, 2020: p. S2213-2198(20)30476-1.

Chao, J.Y., et al., *Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 (COVID-19) at a Tertiary Care Medical Center in New York City*. The Journal of Pediatrics, 2020.

DeBiasi, R.L., et al., *Severe COVID-19 in Children and Young Adults in the Washington, DC Metropolitan Region*. The Journal of Pediatrics, 2020.

Pranata, R., et al., *Impact of Cerebrovascular and Cardiovascular Diseases on Mortality and Severity of COVID-19 – Systematic Review, Meta-analysis, and Meta-regression*. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2020. 29(8): p. 104949-104949.

Wang, B., et al., *Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis*. Aging, 2020. 12(7): p. 6049-6057.

Ssentongo, P., et al., *The association of cardiovascular disease and other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis*. medRxiv, 2020: p. 2020.05.10.20097253.

Khan, M., et al., *Effects of underlying morbidities on the occurrence of deaths in COVID-19 patients: A systematic review and meta-analysis*. medRxiv, 2020: p. 2020.05.08.20095968.

Martins-Filho, P.R., C.S.S. Tavares, and V.S. Santos, *Factors associated with mortality in patients with COVID-19. A quantitative evidence synthesis of clinical and laboratory data*. European journal of internal medicine, 2020. 76: p. 97-99.

Shi, S., et al., *Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China*. JAMA Cardiology, 2020.

Wang, L., et al., *Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up*. Journal of Infection, 2020. 80(6): p. 639-645.

Killerby ME et al., *Characteristics Associated with Hospitalization Among Patients with COVID-19 — Metropolitan Atlanta, Georgia, March–April 2020*. MMWR Morbidity and Mortality Weekly Report, 2020

Guan, W.J., et al., *Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis*. European Respiratory Journal, 2020. 55(5).

Kim, L., et al., *Interim Analysis of Risk Factors for Severe Outcomes among a Cohort of Hospitalized Adults Identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET)*. medRxiv, 2020: p. 2020.05.18.20103390.

Pranata, R., et al., *Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-*

regression. Journal of the Renin-Angiotensin-Aldosterone System, 2020. 21(2): p. 1470320320926899.

Matsushita, K., et al., *The relationship of COVID-19 severity with cardiovascular disease and its traditional risk factors: A systematic review and meta-analysis*. medRxiv, 2020: p. 2020.04.05.20054155.

Yang, Z., et al., *Coronavirus disease 2019 (COVID-19) and pregnancy: a systematic review*. The Journal of Maternal-Fetal & Neonatal Medicine, 2020: p. 1-4.

Li, N., et al., *Maternal and neonatal outcomes of pregnant women with COVID-19 pneumonia: a case-control study*. Clinical Infectious Diseases, 2020.

Collin, J., et al., *Public Health Agency of Sweden's Brief Report: Pregnant and postpartum women with severe acute respiratory syndrome coronavirus 2 infection in intensive care in Sweden*. 2020. 99(7): p. 819-822.

Yan, J., et al., *Coronavirus disease 2019 in pregnant women: a report based on 116 cases*. American Journal of Obstetrics and Gynecology, 2020.

Breslin, N., et al., *Coronavirus disease 2019 infection among asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an affiliated pair of New York City hospitals*. American Journal of Obstetrics & Gynecology MFM, 2020. 2(2, Supplement): p. 100118.

Chen, L., et al., *Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China*. 2020. 382(25): p. e100.

Pierce-Williams, R.A.M., et al., *Clinical course of severe and critical COVID-19 in hospitalized pregnancies: a US cohort study*. American Journal of Obstetrics & Gynecology MFM, 2020: p. 100134.

Savasi, V.M., et al., *Clinical Findings and Disease Severity in Hospitalized Pregnant Women With Coronavirus Disease 2019 (COVID-19)*. Obstet Gynecol, 2020.

Ellington S, Strid P, Tong VT, et al. *Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States, January 22–June 7, 2020*. MMWR Morb Mortal Wkly Rep 2020;69:769–75.

Patanavanich, R. and S.A. Glantz, *Smoking Is Associated With COVID-19 Progression: A Meta-analysis*. Nicotine & Tobacco Research, 2020.

Guo, F.R., *Active smoking is associated with severity of coronavirus disease 2019 (COVID-19): An update of a meta-analysis*. Tobacco Induced Diseases, 2020. 18: p. 37.

Zhao, Q., et al., *The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis*. Journal of Medical Virology, 2020.

Lippi, G. and B.M. Henry, *Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19)*. European Journal of Internal Medicine, 2020. 75: p. 107-108.

Di Giorgio, A., et al., *Health status of patients with autoimmune liver disease during SARS-CoV-2 outbreak in northern Italy*. Journal of hepatology, 2020: p. S0168-8278(20)30300-7.

Marlais, M., et al., *The severity of COVID-19 in children on immunosuppressive medication*. The Lancet. Child & adolescent health, 2020: p. 10.1016/S2352-4642(20)30145-0.

Montero-Escribano, P., et al., *Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain*. Multiple sclerosis and related disorders, 2020. 42: p. 102185-102185.

Brenner, E.J., et al., *Corticosteroids, but not TNF Antagonists, are Associated with Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results from an International Registry*. Gastroenterology, 2020: p. 10.1053/j.gastro.2020.05.032.

Michelena, X., et al., *Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs*. Seminars in arthritis and rheumatism, 2020. 50(4): p. 564-570.

Ljungman, P., et al., *The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy*. Bone Marrow Transplantation, 2020.

Härter, G., et al., *COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients*. Infection, 2020: p. 1-6.

Altuntas Aydin, O., H. Kumbasar Karaosmanoglu, and K. Kart Yasar, *HIV/SARS-CoV-2 coinfecting patients in Istanbul, Turkey*. Journal of Medical Virology, 2020.

Soresina, A., et al., *Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover*. Pediatric Allergy and Immunology, 2020.

Gao, Y., et al., *Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis*. The Journal of infection, 2020: p. S0163-4453(20)30294-2.

Parri, N., M. Lenge, and D. Buonsenso, *Children with Covid-19 in Pediatric Emergency Departments in Italy*. New England Journal of Medicine, 2020.

Mantovani, A., G. Beatrice, and A. Dalbeni, *Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis*. 2020. 40(6): p. 1316-1320.

Moon, A.M., et al., *High Mortality Rates for SARS-CoV-2 Infection in Patients with Pre-existing Chronic Liver Disease and Cirrhosis: Preliminary Results from an International Registry*. Journal of Hepatology, 2020.

Ji, D., et al., *Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study*. J Hepatol, 2020.

Garrido, I., R. Liberal, and G. Macedo, *Review article: COVID-19 and liver disease—what we know on 1st May 2020*. Alimentary Pharmacology & Therapeutics, 2020.

Shekerdemian, L.S., et al., *Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units*. JAMA Pediatrics, 2020.

Cosgriff, R., et al., *A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis*. Journal of Cystic Fibrosis, 2020.

Alsaied T, Aboulhosen JA, Cotts TB, et al. Coronavirus Disease 2019 (COVID-19) Pandemic Implications in Pediatric and Adult Congenital Heart Disease. J Am Heart Assoc. 2020;9(12):e017224. doi:10.1161/JAHA.120.017224

Sanna, G., Serrau, G., Bassareo, P.P. et al. Children's heart and COVID-19: Up-to-date evidence in the form of a systematic review. Eur J Pediatr 179, 1079–1087 (2020).

Sabatino, J.; Ferrero, P.; Chessa, M.; Bianco, F.; Ciliberti, P.; Secinaro, A.; Oreto, L.; Avesani, M.; Bucciarelli, V.; Calcaterra, G.; Calabrò, M.P.; Russo, M.G.; Bassareo, P.P.; Guccione, P.; Indolfi, C.; Di Salvo, G. COVID-19 and Congenital Heart Disease: Results from a Nationwide Survey. J. Clin. Med. 2020, 9, 1774.

DeBiasi RL, Song X, Delaney M, et al. Severe COVID-19 in Children and Young Adults in the Washington, DC Metropolitan Region [published online ahead of print, 2020 May 13]. J Pediatr. 2020;10.1016/j.jpeds.2020.05.007. doi:10.1016/j.jpeds.2020.05.007

Chao, J. Y., Derespina, K. R., Herold, B. C., Goldman, D. L., Aldrich, M., Weingarten, J., ... & Medar, S. S. (2020). Clinical characteristics and outcomes of hospitalized and critically ill children and adolescents with coronavirus disease 2019 (COVID-19) at a Tertiary Care Medical Center in New York City. *The Journal of Pediatrics*.

Motta, I., et al., *SARS-CoV-2 infection in beta thalassemia: Preliminary data from the Italian experience*. American Journal of Hematology, 2020.

Karimi, M., et al., *Prevalence and Mortality due to Outbreak of Novel Coronavirus Disease (COVID-19) in β -Thalassemias: The Nationwide Iranian Experience*.